Back to search

Ireland· IE-PA-EU/1/12/783/001-003

Zyclara 3.75% cream

A imiquimod product containing imiquimod, registered in Ireland by Viatris Healthcare Limited. The same ATC class is registered in 16 of our 19 countries.

ATC D06BB10

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedZyclara 3.75% creamATCD06BB10REGISTER NO.IE-PA-EU/1/12/783/001…PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Imiquimod is registered in 16 of 19 countries.

Countries holding a registration under ATC D06BB10 (imiquimod), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 10 of them publish a price we can compare per daily dose

Imiquimod · ATC D06BB10

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Imiquimod
Manufacturer
Viatris Healthcare Limited
Country
Ireland (IE)
ATC code
D06BB10
ATC class
Imiquimod
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/12/783/001-003

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

74 interactions on record for imiquimod.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Imiquimod · interactions on record

74 records

  • 1 severe
  • 3 moderate
  • 70 info

Most severe, free to view

  • Aminolevulinic acidL01XD04severe
  • Porfimer sodiumL01XD01moderate
  • MethoxsalenL01XD10moderate
  • VerteporfinS01LA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Imiquimod in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All imiquimod products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Austria · Imikeraderm
  • Cyprus · Modiwart
  • Germany · Aksunim, Imikeraderm
  • Spain · Imikeraderm, Imunocare
  • United Kingdom (Northern Ireland) · Bascellex
  • Greece · Modiwart, Quimodia
  • Iceland · Aldara, Zyclara
  • Italy · Imunocare
  • Liechtenstein · Aldara, Zyclara
  • Netherlands · Bascellex
  • Norway · Aldara, Bascellex
  • Poland · Imikeraderm
  • Portugal · Imicare
  • Sweden · Bascellex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c821fac1-b144-4842-a963-9c8f7848a6fc
GET /v1/drugs/c821fac1-b144-4842-a963-9c8f7848a6fc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Cream",
  "routes": [
    "Cutaneous use"
  ],
  "source": "hpra",
  "atc_all": [
    "D06BB",
    "D06BB10"
  ],
  "strength": null,
  "pa_number": "EU/1/12/783/001-003",
  "substances": [
    "Imiquimod"
  ],
  "legal_basis": "Hybrid application (Article 10(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "23/08/2012",
  "dispensing_status": "Product subject to prescription which may be renewed (B)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about imiquimod.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.